BofA/Merrill Lynch Upgrades Edwards Lifesciences (EW) to Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. BILL
4. MRK
5. MRNA
6. ADI
7. LOW
8. COTY
9. RARE
10. TJX

Go back to BofA/Merrill Lynch Upgrades Edwards Lifesciences (EW) to Buy

Edwards Lifesciences (EW) PT Raised to $140 at Canaccord Genuity

July 27, 2016 10:15 AM EDT

Canaccord Genuity analyst Jason Mills reiterated a Buy rating and raised his price target on Edwards Lifesciences (NYSE: EW) to $140.00 (from $132.00) following the latest 'beat and raise'.

Mills commented, ""We view EW as one of the most attractive large-cap growth ideas in... More

Edwards Lifesciences (EW) PT Raised to $139 at UBS Amid Strong Q2

July 27, 2016 8:14 AM EDT

UBS analyst Matt Miksic reiterated a Buy rating and boosted his price target on Edwards Lifesciences (NYSE: EW) to $139.00 (from $135.00) following strong results after the close.

Miksic commented, "Our intra-quarter checks indicated strong volume growth, contrary to Street concerns over third-party data indicating otherwise. However, EW delivered results... More

Edwards Lifesciences (EW): THV Is The Key, Raising PT - Leerink

July 27, 2016 7:15 AM EDT

Leerink Partners analyst, Danielle Antalffy, reiterated her Outperform rating on shares of Edwards Lifesciences (NYSE: EW) after the company reported better than-expected sales (9th consecutive quarter of sales outperformance) -- with 2Q16 adjusted sales of $759.3M (+22.1% y/y, +22.9% ex. FX), ~$35M ahead of consensus. She also raised her price target to $130.00... More

Edwards Lifesciences (EW) Tops Q2 EPS by 6c; Guides Above

July 26, 2016 4:17 PM EDT

Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.76, $0.06 better than the analyst estimate of $0.70. Revenue for the quarter came in at $759.3 million versus the consensus estimate of $724.26 million.

"We are very pleased to report strong second quarter performance, which reflected significant growth in... More